All In Biotech

Drug Trial Radar · NCT04656288

A Study in Healthy Men to Test if Different Formulations of BI 764198 With or Without Food Influence the Amount of BI 764198 in the Blood

A Two-part Phase I Trial Investigating the Relative Bioavailability and Food Effect of Different Oral Formulations of BI 764198 in Healthy Subjects (an Open-label, Single-dose, Randomised, Crossover Study)

Last checked: Nov 20, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

28

Actual

Start

Jan 15, 2021

Primary completion

Mar 15, 2021

Study completion Mar 15, 2021

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Dec 7, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

BI 764198 is intended to be used in patients hospitalized for COVID-19 at risk of respiratory complications. The present trial will investigate the relative bioavailability of BI 764198 administered as capsules versus tablets in a first part, and the relative bioavailability and food effect of four oral formulations: the newly developed tablet formulation under fed and fasted conditions as well as suspension from capsules and suspension from tablets in a second part.

Conditions

  • Healthy

Interventions

  • BI 764198 - Formula ADrug

    BI 764198

  • BI 764198 - Formula BDrug

    BI 764198

  • BI 764198 - Formula CDrug

    BI 764198

  • BI 764198 - Formula DDrug

    BI 764198

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point)Time frame: up to 4 days per period
  2. Part 1: Cmax (maximum measured concentration of the analyte in plasma)Time frame: up to 4 days per period
  3. Part 2: AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point)Time frame: up to 5 days per period
  4. Part 2: Cmax (maximum measured concentration of the analyte in plasma)Time frame: up to 5 days per period

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • SGS Belgium NV Research Unit Stuivenberg

    Antwerp, Belgium

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.